Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AtriCure (ATRC) EBITDA (2016 - 2025)

Historic EBITDA for AtriCure (ATRC) over the last 17 years, with Q3 2025 value amounting to -$443000.0.

  • AtriCure's EBITDA rose 9403.85% to -$443000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.1 million, marking a year-over-year increase of 2394.12%. This contributed to the annual value of -$44.7 million for FY2024, which is 6367.29% down from last year.
  • Per AtriCure's latest filing, its EBITDA stood at -$443000.0 for Q3 2025, which was up 9403.85% from -$5.2 million recorded in Q2 2025.
  • AtriCure's EBITDA's 5-year high stood at $97.0 million during Q3 2021, with a 5-year trough of -$17.7 million in Q1 2022.
  • For the 5-year period, AtriCure's EBITDA averaged around -$4.4 million, with its median value being -$8.6 million (2023).
  • As far as peak fluctuations go, AtriCure's EBITDA soared by 212214.35% in 2021, and later crashed by 18939.75% in 2023.
  • AtriCure's EBITDA (Quarter) stood at -$14.5 million in 2021, then soared by 79.48% to -$3.0 million in 2022, then crashed by 189.4% to -$8.6 million in 2023, then crashed by 91.39% to -$16.5 million in 2024, then skyrocketed by 97.31% to -$443000.0 in 2025.
  • Its EBITDA stands at -$443000.0 for Q3 2025, versus -$5.2 million for Q2 2025 and -$5.9 million for Q1 2025.